Journal Publications

Export 124 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
2015
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. Huntington S, Thorne C, Newell M, Anderson J, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2015 Nov, Volume 29, Issue 17, p.2269-78, (2015)
Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. Huntington S, Thorne C, Newell M, Anderson J, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2015 Apr 24, Volume 29, Issue 7, p.801-9, (2015)
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Mocroft A, Lundgren J, Antinori A, Monforte A, Brännström J, Bonnet F, Brockmeyer N, Casabona J, Castagna A, Costagliola D et al. Euro Surveill, 2015, Volume 20, Issue 47, (2015)
2014
End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study. Gathogo E, Jose S, Jones R, Levy J, Mackie N, Booth J, Connolly J, Johnson M, Leen C, Williams D et al. J Acquir Immune Defic Syndr, 2014 Oct 01, Volume 67, Issue 2, p.177-80, (2014)
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. Klein M, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan D, Walmsley S et al. CMAJ Open, 2014 Oct, Volume 2, Issue 4, p.E318-29, (2014)
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. May M, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R et al. AIDS, 2014 May 15, Volume 28, Issue 8, p.1193-202, (2014)
The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C, Gompels M, Gilson R et al. HIV Med, 2014 May, Volume 15, Issue 5, p.311-6, (2014)
The contribution of viral genotype to plasma viral set-point in HIV infection. Hodcroft E, Hadfield J, Fearnhill E, Phillips A, Dunn D, O'Shea S, Pillay D and Brown A. PLoS Pathog, 2014 May, Volume 10, Issue 5, p.e1004112, (2014)
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Engsig F, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G et al. Clin Infect Dis, 2014 May, Volume 58, Issue 9, p.1312-21, (2014)
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. O'Connor J, Smith C, Lampe F, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R et al. AIDS, 2014 Mar 27, Volume 28, Issue 6, p.919-24, (2014)
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. . AIDS, 2014 Mar 13, Volume 28, Issue 5, p.773-80, (2014)
Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women. Huntington S, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. BMC Infect Dis, 2014 Mar 04, Volume 14, p.127, (2014)
Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. . AIDS, 2014 Jun 01, Volume 28, Issue 9, p.1351-6, (2014)
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F, Nelson M, Gompels M et al. AIDS, 2014 Jun 01, Volume 28, Issue 9, p.1333-9, (2014)
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C and Nelson M. J Infect, 2014 Jan, Volume 68, Issue 1, p.77-84, (2014)
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. Jose S, Hamzah L, Campbell L, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P et al. J Infect Dis, 2014 Aug 01, Volume 210, Issue 3, p.363-73, (2014)
2013
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. Mackie N, Dunn D, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C and Geretti A. AIDS, 2013 Sep 10, Volume 27, Issue 14, p.2245-53, (2013)
HLA B*5701 status, disease progression, and response to antiretroviral therapy. . AIDS, 2013 Oct 23, Volume 27, Issue 16, p.2587-92, (2013)
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D et al. Clin Infect Dis, 2013 Oct, Volume 57, Issue 7, p.1038-47, (2013)
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. Dolling D, Dunn D, Sutherland K, Pillay D, Mbisa J, Parry C, Post F, Sabin C and Cane P. J Antimicrob Chemother, 2013 Oct, Volume 68, Issue 10, p.2339-43, (2013)
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. Santoro M, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G et al. HIV Med, 2013 Oct, Volume 14, Issue 9, p.571-7, (2013)
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, De Luca A, Jansen K et al. J Infect Dis, 2013 Mar 01, Volume 207, Issue 5, p.759-67, (2013)
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. Winston A, Jose S, Gibbons S, Back D, Stöhr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R et al. J Antimicrob Chemother, 2013 Jun, Volume 68, Issue 6, p.1354-9, (2013)
Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. Huntington S, Thorne C, Bansi L, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2013 Jan 02, Volume 27, Issue 1, p.95-103, (2013)
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Dolling D, Dunn D, Geretti A and Sabin C. Clin Infect Dis, 2013 Jan, Volume 56, Issue 1, p.162-3, (2013)